Brian Tanquilut
A.J. Rice
Kevin Fischbeck
Jeff Silber
Jorge A. Caballero
Director Since: 2021
Business Experience and Qualifications: The Board has concluded that Mr. Caballero is qualified to serve on the Board, because he possesses a strong audit, financial and risk management background with extensive experience in mergers and acquisitions, which is a critical component of AMN’s growth strategy. The Board has also determined that Mr. Caballero qualifies as a financial expert and appointed him as a member of its Audit Committee.
Mr. Caballero is an accomplished global business executive who served as Managing Partner of Deloitte’s Business Tax Services U.S.-India practice until his retirement in June 2019. During his 32-year tenure at Deloitte LLP, Mr. Caballero served in many capacities as a state and regional tax managing partner prior to assuming a global role. He joined Deloitte as a tax manager in 1987 and was admitted to the partnership three years later where he led teams from tax, audit, consulting, and risk. In addition, Mr. Caballero served as a Tax Managing Partner for the State of New Jersey from 2003 to 2011 and as Assistant Vice President of Tax at Beneficial Corporation from 1983 to 1986, and as a Senior Consultant at PricewaterhouseCoopers from 1979 to 1982.
Board Experience: Mr. Caballero served as Chief Diversity Officer on the board of Deloitte Tax LLP, as well as a board of directors and Finance Committee chair on the boards of United Way, Essex and West Hudson in New Jersey, and The College of New Jersey. He also served on the boards of New Jersey State Board of Accountancy, Jersey Battered Women’s Service and the Hispanic Association of Colleges and Universities.
Sylvia Trent-Adams
Director Since: 2020
Business Experience and Qualifications: The Board has concluded that Rear Admiral Trent-Adams, PhD, RN, FAAN, is qualified to serve on the Board because of her distinguished career as a healthcare professional and leader. She served in the U.S. Public Health Service Commissioned Corps from 1992-2020, which included service as Deputy Surgeon General and Acting Surgeon General of the United States. In leadership roles in the U.S. Department of Health and Human Services, including as Principal Deputy Assistant Secretary for Health prior to her recent retirement, Rear Admiral Trent-Adams’ decades of service have included directing and coordinating major federal health programs and developing policy and legislative priorities for our nation’s public health. She served the Public Health Service Commissioned Corps in many capacities, including as deputy associate administrator for the HIV/AIDS Bureau, where she assisted in managing the Ryan White HIV/AIDS Program, a landmark program of primary medical care, medication, and essential support services for more than half a million uninsured people with HIV. Prior to joining the Public Health Service, Rear Admiral Trent-Adams was a nurse officer in the U.S. Army, with a clinical practice in trauma, oncology, community health, and infectious disease. Among her many awards and decorations, Rear Admiral Trent-Adams has received the Meritorious Service Medal for leadership for her work on the Ebola outbreak in West Africa, and the International Red Cross Florence Nightingale Medal, the highest international honor given to a nurse. After leaving the Public Health Service in August 2020, Rear Admiral Trent-Adams is now the Executive Vice President and Chief Strategy Officer for the University of North Texas Health Science Center.
Martha H. Marsh
Director Since: 2010
Business Experience and Qualifications: The Board has concluded that Ms. Marsh is qualified to serve on the Board because she has extensive “C-suite” leadership and expertise in the healthcare industry. Ms. Marsh’s experience and understanding of the challenges and opportunities of large healthcare facilities are immensely useful in directing our strategy to innovate and provide enhanced and expanded workforce solutions service offerings to meet our clients’ evolving needs. Ms. Marsh served as President and CEO of Stanford Hospital and Clinics for eight years, from April 2002 until her retirement in August 2010. Previously, Ms. Marsh served as the CEO of UC Davis Medical Center and the Chief Operating Officer of the UC Davis Health System from 1999 to 2002. Prior to that time, she served as the Senior Vice President for Professional Services and Managed Care at the University of Pennsylvania Health System, and before that as President and CEO of Matthew Thornton Health Plan in Nashua, New Hampshire.
Board Experience: From 2012 through 2019, Ms. Marsh served as a director of Owens & Minor, Inc. as the Chairperson of the Governance and Nominating Committee and also served on its Compensation and Benefits Committee. Since October 2015, she has served as a director of Edwards Lifesciences Corporation and is a member of its Compensation and Governance Committee. She also serves on the Board and the Compensation Committee of Teichert, a privately-held company. Prior to Thoratec Corporation’s acquisition by St. Jude Medical in 2015, she had served on Thoratec’s Board. Ms. Marsh is a past Chair of the Board of Trustees for the California Hospital Association and the California Association of Hospitals and Health Systems and a former director of Ascension Healthcare Network, a privately-held company.
Daphne E. Jones
Director Since: 2018
Business Experience and Qualifications: The Board has concluded that Ms. Jones is qualified to serve on the Board because she brings considerable information technology, global digital technology use, data management and privacy experience as a seasoned “C-suite” executive with extensive experience in multinational corporations. Ms. Jones’ digital use and technology expertise and experience will be critical to our successful execution of our digital strategies. Ms. Jones serves as the Founder of The Board Curators, LLC, since July 2021, and Founder of Destiny Transformations Group, LLC since April 2018. Ms. Jones served as the Senior Vice President - Digital/Future of Work for GE Healthcare, the healthcare business of GE, from May 2017 to October 2017 and prior to that she served as the Senior Vice President - Chief Information Officer for GE Healthcare Diagnostic Imaging and Services since August 2014. Prior to joining GE Healthcare, Ms. Jones was the Senior Vice President, Chief Information Officer for Hospira, Inc., a provider of pharmaceuticals and infusion technologies, from October 2009 through June 2014. Previously she served as Chief Information Officer at Johnson & Johnson from 2006 to 2009 and served in various information technology roles with Johnson & Johnson from 1997 through 2006. Ms. Jones began her career in sales and systems engineering at IBM.
Board Experience: Ms. Jones serves on the board of Masonite International Corp, where she is a member of the Audit Committee. She also serves on the board of directors for Barnes Group Inc. Ms. Jones previously served on the board of the Thurgood Marshall College Fund, a not-for-profit organization and the nation’s largest organization exclusively representing the Black College Community.
Teri G. Fontenot
Director Since: 2019
Business Experience and Qualifications: The Board has concluded that Ms. Fontenot is qualified to serve on the Board because she brings considerable audit, financial and healthcare experience both as an executive officer and director of healthcare companies. The Board has determined that Ms. Fontenot qualifies as a financial expert and appointed her as a member of its Audit Committee. Since March 2019, Ms. Fontenot has served as CEO Emeritus of Woman’s Hospital, the largest independently-owned women’s and infant’s hospital in the United States providing comprehensive subspecialty services to women. From 1996 to March 2019, Ms. Fontenot served as President and CEO of Woman’s Hospital. From 1992 to 1996, Ms. Fontenot served as the Chief Financial Officer and Executive Vice President of Woman’s Hospital. Under her leadership, Woman’s Hospital became the largest birthing hospital and neonatal intensive care unit in Louisiana. Prior to joining Woman’s Hospital in 1992, Ms. Fontenot served as Chief Financial Officer of three other hospitals located in Louisiana and Florida and is a Certified Public Accountant (inactive).
Board Experience: Ms. Fontenot has served on numerous healthcare boards at a local, state and national level, including the Board of Directors of the Louisiana Hospital Association, and the American Hospital Association where she served as Chairperson in 2012. She held a six-year term on the Advisory Committee on Research on Women’s Health for the National Institutes of Health. Ms. Fontenot is also a director on the board and a member of the Audit Committee of the Baton Rouge Water Company, and a director on the board of Dynamic Infusion Therapy, both private companies, and a director on the board of Orlando Health, Inc., a not-for profit organization. From 2007 to 2019, Ms. Fontenot served on the board of directors of the Sixth District Federal Reserve Bank of Atlanta, including as its Audit Committee chair for two years. Ms. Fontenot currently serves on the board of directors and is a member of the audit committee for Amerisafe. Inc. Additionally, she is a member of the Clinical Quality Committee and Chairperson of the Audit Committee for LHC Group, Inc. She was a member of the board of directors of Landauer (a formerly publicly-held company) until its sale in 2017. She is a Fellow of the American College of Healthcare Executives, where she presents frequently on women’s health and leadership topics.
Mark G. Foletta
Director Since: 2012
Business Experience and Qualifications:The Board has concluded that Mr. Foletta is qualified to serve on the Board, because he brings considerable audit, financial, healthcare and enterprise risk management experience as both an executive officer and director of healthcare companies. The Board has designated Mr. Foletta as a financial expert for its Audit Committee, for which he serves as Chairman. Since February 2017, Mr. Foletta has served as Executive Vice President and Chief Financial Officer of Tocagen Inc. Mr. Foletta served as the Interim Chief Financial Officer of Biocept, Inc., a publicly-traded diagnostics company, from August 2015 to July 2016, and he also served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc. from March 2006 until October 2012. While at Amylin, Mr. Foletta assisted with developing and launching the organization’s initial enterprise risk management assessment. From March 2000 to March 2006, Mr. Foletta served as Vice President, Finance and Chief Financial Officer of Amylin. Mr. Foletta received a Bachelor of Arts from the University of California, Santa Barbara. He is also a Certified Public Accountant (inactive) and a member of the Corporate Directors Forum.
Board Experience:Since November 2014, Mr. Foletta has served on the Board of DexCom, Inc., a publicly-traded company, where he is the Lead Director. From February 2013 through June 2018, Mr. Foletta served as a director of Regulus Therapeutics Inc., and was Chairman of its Audit Committee and a member of its Nominating and Governance Committee. While at Regulus and DexCom, Mr. Foletta helped oversee and guide the launch of each organization’s initial enterprise risk management assessment. Additionally, Mr. Foletta serves as a director of Viacyte, Inc., a privately held company. He previously served as a director and Chairman of the Audit Committee of Ambit Biosciences Corporation (sold in 2014), and also served as a director of Anadys Pharmaceuticals, Inc. (sold in 2011).